Click here to get full coverage on Capital Area District Libraries announces plan to relocate Local History collection - WILX

Capital Area District Libraries announces plan to relocate Local History collection  WILX

Capital Area District Libraries announces plan to relocate Local History collection - WILX

Click here to get full coverage on Does Candel Therapeutics (CADL) Have the Potential to Rally 285.32% as Wall Street Analysts Expect? - Yahoo Finance

Does Candel Therapeutics (CADL) Have the Potential to Rally 285.32% as Wall Street Analysts Expect?  Yahoo Finance

Does Candel Therapeutics (CADL) Have the Potential to Rally 285.32% as Wall Street Analysts Expect? - Yahoo Finance

Click here to get full coverage on $CADL stock is down 9% today. Here's what we see in our data. - Quiver Quantitative

$CADL stock is down 9% today. Here's what we see in our data.  Quiver Quantitative

$CADL stock is down 9% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Hot reads for long summer days: CADL literary experts share recommendations - Lansing State Journal

Hot reads for long summer days: CADL literary experts share recommendations  Lansing State Journal

Hot reads for long summer days: CADL literary experts share recommendations - Lansing State Journal

Click here to get full coverage on Understanding the Setup: (CADL) and Scalable Risk - Stock Traders Daily

Understanding the Setup: (CADL) and Scalable Risk  Stock Traders Daily

Understanding the Setup: (CADL) and Scalable Risk - Stock Traders Daily

Click here to get full coverage on HC Wainwright & Co. Reiterates Candel Therapeutics (CADL) Buy Recommendation - Nasdaq

HC Wainwright & Co. Reiterates Candel Therapeutics (CADL) Buy Recommendation  Nasdaq

HC Wainwright & Co. Reiterates Candel Therapeutics (CADL) Buy Recommendation - Nasdaq

Click here to get full coverage on Candel Therapeutics, Inc.'s (NASDAQ:CADL) latest 15% decline adds to one-year losses, institutional investors may consider drastic measures - simplywall.st

Candel Therapeutics, Inc.'s (NASDAQ:CADL) latest 15% decline adds to one-year losses, institutional investors may consider drastic measures  simplywall.st

Candel Therapeutics, Inc.'s (NASDAQ:CADL) latest 15% decline adds to one-year losses, institutional investors may consider drastic measures - simplywall.st

Click here to get full coverage on Nov 18: Candel Therapeutics (NASDAQ: CADL) to present at Jefferies Healthcare in London - Stock Titan

Nov 18: Candel Therapeutics (NASDAQ: CADL) to present at Jefferies Healthcare in London  Stock Titan

Nov 18: Candel Therapeutics (NASDAQ: CADL) to present at Jefferies Healthcare in London - Stock Titan

Click here to get full coverage on Candel Therapeutics: Potentially The Next Exciting Oncology Story - Seeking Alpha

Candel Therapeutics: Potentially The Next Exciting Oncology Story  Seeking Alpha

Candel Therapeutics: Potentially The Next Exciting Oncology Story - Seeking Alpha

Click here to get full coverage on Public can weigh in on future of CADL's downtown branch as work starts on new strategic plan - WKAR

Public can weigh in on future of CADL's downtown branch as work starts on new strategic plan  WKAR

Public can weigh in on future of CADL's downtown branch as work starts on new strategic plan - WKAR

Click here to get full coverage on Candel Therapeutics highlights 3Q milestones across cancer immunotherapy pipeline - Proactive financial news

Candel Therapeutics highlights 3Q milestones across cancer immunotherapy pipeline  Proactive financial news

Candel Therapeutics highlights 3Q milestones across cancer immunotherapy pipeline - Proactive financial news

Click here to get full coverage on New Analyst Forecast: $CADL Given $24.0 Price Target - Quiver Quantitative

New Analyst Forecast: $CADL Given $24.0 Price Target  Quiver Quantitative

New Analyst Forecast: $CADL Given $24.0 Price Target - Quiver Quantitative

Click here to get full coverage on (CADL) Volatility Zones as Tactical Triggers - Stock Traders Daily

(CADL) Volatility Zones as Tactical Triggers  Stock Traders Daily

(CADL) Volatility Zones as Tactical Triggers - Stock Traders Daily

Click here to get full coverage on Citigroup Maintains Candel Therapeutics (CADL) Buy Recommendation - Nasdaq

Citigroup Maintains Candel Therapeutics (CADL) Buy Recommendation  Nasdaq

Citigroup Maintains Candel Therapeutics (CADL) Buy Recommendation - Nasdaq

Click here to get full coverage on Candel Therapeutics (CADL) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance

Candel Therapeutics (CADL) Upgraded to Strong Buy: Here's What You Should Know  Yahoo Finance

Candel Therapeutics (CADL) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance

Click here to get full coverage on ‘Better Living Through Birding’ chosen for Greater Lansing shared reading experience - Lansing State Journal

‘Better Living Through Birding’ chosen for Greater Lansing shared reading experience  Lansing State Journal

‘Better Living Through Birding’ chosen for Greater Lansing shared reading experience - Lansing State Journal

Click here to get full coverage on Appointment: Bali Pulendran, Ph.D. joins Candel's RAB; will advise on CAN-2409 & CAN-3110 - Stock Titan

Appointment: Bali Pulendran, Ph.D. joins Candel's RAB; will advise on CAN-2409 & CAN-3110  Stock Titan

Appointment: Bali Pulendran, Ph.D. joins Candel's RAB; will advise on CAN-2409 & CAN-3110 - Stock Titan

Click here to get full coverage on $CADL stock is up 15% today. Here's what we see in our data. - Nasdaq

$CADL stock is up 15% today. Here's what we see in our data.  Nasdaq

$CADL stock is up 15% today. Here's what we see in our data. - Nasdaq

Click here to get full coverage on Candel Therapeutics, Inc. (CADL) to Present Positive Phase 3 Prostate Cancer Data at ASCO 2025 - Yahoo Finance

Candel Therapeutics, Inc. (CADL) to Present Positive Phase 3 Prostate Cancer Data at ASCO 2025  Yahoo Finance

Candel Therapeutics, Inc. (CADL) to Present Positive Phase 3 Prostate Cancer Data at ASCO 2025 - Yahoo Finance

Click here to get full coverage on LifeSci Capital Initiates Coverage of Candel Therapeutics (CADL) with Outperform Recommendation - Nasdaq

LifeSci Capital Initiates Coverage of Candel Therapeutics (CADL) with Outperform Recommendation  Nasdaq

LifeSci Capital Initiates Coverage of Candel Therapeutics (CADL) with Outperform Recommendation - Nasdaq

Click here to get full coverage on Candel Therapeutics Raises $15M with Strong Insider Backing to Advance Prostate Cancer Treatment - Stock Titan

Candel Therapeutics Raises $15M with Strong Insider Backing to Advance Prostate Cancer Treatment  Stock Titan

Candel Therapeutics Raises $15M with Strong Insider Backing to Advance Prostate Cancer Treatment - Stock Titan

Click here to get full coverage on Capital Area District Library Aurelius Branch to host summer events - WILX

Capital Area District Library Aurelius Branch to host summer events  WILX

Capital Area District Library Aurelius Branch to host summer events - WILX

Click here to get full coverage on Candel Therapeutics (Nasdaq: CADL) Sets Virtual R&D Event on Immuno-Oncology, CAN-2409 and CAN-3110 - Stock Titan

Candel Therapeutics (Nasdaq: CADL) Sets Virtual R&D Event on Immuno-Oncology, CAN-2409 and CAN-3110  Stock Titan

Candel Therapeutics (Nasdaq: CADL) Sets Virtual R&D Event on Immuno-Oncology, CAN-2409 and CAN-3110 - Stock Titan

Click here to get full coverage on Candel Therapeutics Insider Ups Holding By 22% During Year - simplywall.st

Candel Therapeutics Insider Ups Holding By 22% During Year  simplywall.st

Candel Therapeutics Insider Ups Holding By 22% During Year - simplywall.st

Click here to get full coverage on Candel Therapeutics Has A Protracted, But Real, Timeline To Approval Now - Seeking Alpha

Candel Therapeutics Has A Protracted, But Real, Timeline To Approval Now  Seeking Alpha

Candel Therapeutics Has A Protracted, But Real, Timeline To Approval Now - Seeking Alpha

Click here to get full coverage on CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer - Yahoo Finance

CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer  Yahoo Finance

CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer - Yahoo Finance

Click here to get full coverage on Citi Maintains Candel Therapeutics(CADL.US) With Buy Rating, Maintains Target Price $24 - 富途牛牛

Citi Maintains Candel Therapeutics(CADL.US) With Buy Rating, Maintains Target Price $24  富途牛牛

Citi Maintains Candel Therapeutics(CADL.US) With Buy Rating, Maintains Target Price $24 - 富途牛牛

Click here to get full coverage on Candel trial shows promise for gene therapy in prostate cancer | NASDAQ:CADL - Proactive financial news

Candel trial shows promise for gene therapy in prostate cancer | NASDAQ:CADL  Proactive financial news

Candel trial shows promise for gene therapy in prostate cancer | NASDAQ:CADL - Proactive financial news

Click here to get full coverage on Why CADL stock is recommended by analysts - July 2025 Reactions & Reliable Volume Spike Alerts - Улправда

Why CADL stock is recommended by analysts - July 2025 Reactions & Reliable Volume Spike Alerts  Улправда

Why CADL stock is recommended by analysts - July 2025 Reactions & Reliable Volume Spike Alerts - Улправда

Click here to get full coverage on Candel Therapeutics: CAN-2409’s Promising Progress Deserves An Upgrade (NASDAQ:CADL) - Seeking Alpha

Candel Therapeutics: CAN-2409’s Promising Progress Deserves An Upgrade (NASDAQ:CADL)  Seeking Alpha

Candel Therapeutics: CAN-2409’s Promising Progress Deserves An Upgrade (NASDAQ:CADL) - Seeking Alpha

Click here to get full coverage on Candel Therapeutics to Present New Insights on Immunotherapy at SITC 40th Annual Meeting | CADL Stock News - Quiver Quantitative

Candel Therapeutics to Present New Insights on Immunotherapy at SITC 40th Annual Meeting | CADL Stock News  Quiver Quantitative

Candel Therapeutics to Present New Insights on Immunotherapy at SITC 40th Annual Meeting | CADL Stock News - Quiver Quantitative

Click here to get full coverage on Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights - GlobeNewswire

Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights  GlobeNewswire

Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights - GlobeNewswire

Click here to get full coverage on Candel Therapeutics, Inc. CEO Paul Peter Tak to Present at Jefferies Global Healthcare Conference 2025 - Quiver Quantitative

Candel Therapeutics, Inc. CEO Paul Peter Tak to Present at Jefferies Global Healthcare Conference 2025  Quiver Quantitative

Candel Therapeutics, Inc. CEO Paul Peter Tak to Present at Jefferies Global Healthcare Conference 2025 - Quiver Quantitative

Click here to get full coverage on Institutional investors in Candel Therapeutics, Inc. (NASDAQ:CADL) see US$153m decrease in market cap last week, although long-term gains have benefitted them. - Yahoo Finance

Institutional investors in Candel Therapeutics, Inc. (NASDAQ:CADL) see US$153m decrease in market cap last week, although long-term gains have benefitted them.  Yahoo Finance

Institutional investors in Candel Therapeutics, Inc. (NASDAQ:CADL) see US$153m decrease in market cap last week, although long-term gains have benefitted them. - Yahoo Finance

Click here to get full coverage on Candel Therapeutics to highlight immunotherapy advances at SITC 2025 - Proactive financial news

Candel Therapeutics to highlight immunotherapy advances at SITC 2025  Proactive financial news

Candel Therapeutics to highlight immunotherapy advances at SITC 2025 - Proactive financial news

Click here to get full coverage on Can CADL stock rebound after recent weakness - July 2025 Selloffs & Reliable Intraday Trade Alerts - Улправда

Can CADL stock rebound after recent weakness - July 2025 Selloffs & Reliable Intraday Trade Alerts  Улправда

Can CADL stock rebound after recent weakness - July 2025 Selloffs & Reliable Intraday Trade Alerts - Улправда

Click here to get full coverage on Candel Therapeutics, Inc. Announces Virtual Research and Development Day for December 5, 2025 - Quiver Quantitative

Candel Therapeutics, Inc. Announces Virtual Research and Development Day for December 5, 2025  Quiver Quantitative

Candel Therapeutics, Inc. Announces Virtual Research and Development Day for December 5, 2025 - Quiver Quantitative

Click here to get full coverage on Candel Therapeutics, Inc. Announces Oral Presentation of CAN-2409 Data at 2025 ASTRO Annual Meeting - Quiver Quantitative

Candel Therapeutics, Inc. Announces Oral Presentation of CAN-2409 Data at 2025 ASTRO Annual Meeting  Quiver Quantitative

Candel Therapeutics, Inc. Announces Oral Presentation of CAN-2409 Data at 2025 ASTRO Annual Meeting - Quiver Quantitative

Click here to get full coverage on Citi Reaffirms Their Buy Rating on Candel Therapeutics (CADL) - The Globe and Mail

Citi Reaffirms Their Buy Rating on Candel Therapeutics (CADL)  The Globe and Mail

Citi Reaffirms Their Buy Rating on Candel Therapeutics (CADL) - The Globe and Mail

Click here to get full coverage on Candel Therapeutics secures $130M to fund lead program – ICYMI - Proactive financial news

Candel Therapeutics secures $130M to fund lead program – ICYMI  Proactive financial news

Candel Therapeutics secures $130M to fund lead program – ICYMI - Proactive financial news

Click here to get full coverage on Can CADL stock hit record highs again - Weekly Volume Report & Risk Controlled Daily Trade Plans - Улправда

Can CADL stock hit record highs again - Weekly Volume Report & Risk Controlled Daily Trade Plans  Улправда

Can CADL stock hit record highs again - Weekly Volume Report & Risk Controlled Daily Trade Plans - Улправда

Click here to get full coverage on Can CADL stock rebound after recent weakness - Watch List & Stock Market Timing Techniques - Улправда

Can CADL stock rebound after recent weakness - Watch List & Stock Market Timing Techniques  Улправда

Can CADL stock rebound after recent weakness - Watch List & Stock Market Timing Techniques - Улправда

Click here to get full coverage on 30% Better Survival: Candel's Breakthrough Prostate Cancer Drug Shows Success Across All Radiation Types - Stock Titan

30% Better Survival: Candel's Breakthrough Prostate Cancer Drug Shows Success Across All Radiation Types  Stock Titan

30% Better Survival: Candel's Breakthrough Prostate Cancer Drug Shows Success Across All Radiation Types - Stock Titan

Click here to get full coverage on Will CADL stock see insider buying - Price Channel Trading & Small Budget Trading Tips - Улправда

Will CADL stock see insider buying - Price Channel Trading & Small Budget Trading Tips  Улправда

Will CADL stock see insider buying - Price Channel Trading & Small Budget Trading Tips - Улправда

Click here to get full coverage on Candel Therapeutics, Inc. (CADL) Stock Analysis: A Remarkable 285% Potential Upside Awaits Investors - DirectorsTalk Interviews

Candel Therapeutics, Inc. (CADL) Stock Analysis: A Remarkable 285% Potential Upside Awaits Investors  DirectorsTalk Interviews

Candel Therapeutics, Inc. (CADL) Stock Analysis: A Remarkable 285% Potential Upside Awaits Investors - DirectorsTalk Interviews

Click here to get full coverage on Discover, reflect, celebrate: 20 Black History Month reads CADL librarians recommend - Lansing State Journal

Discover, reflect, celebrate: 20 Black History Month reads CADL librarians recommend  Lansing State Journal

Discover, reflect, celebrate: 20 Black History Month reads CADL librarians recommend - Lansing State Journal

Click here to get full coverage on Candel Therapeutics: Oncolytic Immunotherapy Showing Broad Efficacy In Tough Tumors - Seeking Alpha

Candel Therapeutics: Oncolytic Immunotherapy Showing Broad Efficacy In Tough Tumors  Seeking Alpha

Candel Therapeutics: Oncolytic Immunotherapy Showing Broad Efficacy In Tough Tumors - Seeking Alpha

Click here to get full coverage on Join the summer reading challenge with Capital Area District Libraries - WILX

Join the summer reading challenge with Capital Area District Libraries  WILX

Join the summer reading challenge with Capital Area District Libraries - WILX

Click here to get full coverage on Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors - Chartmill

Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors  Chartmill

Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors - Chartmill

Click here to get full coverage on Candel Therapeutics: I Say Stay The Course Despite The Market's Rebuke Of Positive Pancreatic Data - Seeking Alpha

Candel Therapeutics: I Say Stay The Course Despite The Market's Rebuke Of Positive Pancreatic Data  Seeking Alpha

Candel Therapeutics: I Say Stay The Course Despite The Market's Rebuke Of Positive Pancreatic Data - Seeking Alpha

Click here to get full coverage on Can CADL stock hit record highs again - Market Trend Review & Verified Short-Term Plans - Улправда

Can CADL stock hit record highs again - Market Trend Review & Verified Short-Term Plans  Улправда

Can CADL stock hit record highs again - Market Trend Review & Verified Short-Term Plans - Улправда

Click here to get full coverage on Candel Therapeutics secures $130M loan facility to advance clinical pipeline | NASDAQ:CADL - Proactive financial news

Candel Therapeutics secures $130M loan facility to advance clinical pipeline | NASDAQ:CADL  Proactive financial news

Candel Therapeutics secures $130M loan facility to advance clinical pipeline | NASDAQ:CADL - Proactive financial news

Click here to get full coverage on Candel Therapeutics (NASDAQ:CADL) Shares Little Changed on Clinical-Stage Progress - Kalkine Media

Candel Therapeutics (NASDAQ:CADL) Shares Little Changed on Clinical-Stage Progress  Kalkine Media

Candel Therapeutics (NASDAQ:CADL) Shares Little Changed on Clinical-Stage Progress - Kalkine Media

Click here to get full coverage on Will CADL stock see insider buying - Debt-to-Equity Ratio Analysis & Big Returns Low Cost - Улправда

Will CADL stock see insider buying - Debt-to-Equity Ratio Analysis & Big Returns Low Cost  Улправда

Will CADL stock see insider buying - Debt-to-Equity Ratio Analysis & Big Returns Low Cost - Улправда

Click here to get full coverage on Candel Therapeutics: Entering Its Pivotal Year (NASDAQ:CADL) - Seeking Alpha

Candel Therapeutics: Entering Its Pivotal Year (NASDAQ:CADL)  Seeking Alpha

Candel Therapeutics: Entering Its Pivotal Year (NASDAQ:CADL) - Seeking Alpha

Click here to get full coverage on Candel Therapeutics Stock Soars On FDA’s RMAT Designation For Prostate Cancer Therapy - Stocktwits

Candel Therapeutics Stock Soars On FDA’s RMAT Designation For Prostate Cancer Therapy  Stocktwits

Candel Therapeutics Stock Soars On FDA’s RMAT Designation For Prostate Cancer Therapy - Stocktwits

Click here to get full coverage on Can CADL stock hit record highs again - 2025 Market Sentiment & Real-Time Price Movement Reports - Улправда

Can CADL stock hit record highs again - 2025 Market Sentiment & Real-Time Price Movement Reports  Улправда

Can CADL stock hit record highs again - 2025 Market Sentiment & Real-Time Price Movement Reports - Улправда

Click here to get full coverage on Candel Reports 88 Percent Q2 Loss Drop - The Globe and Mail

Candel Reports 88 Percent Q2 Loss Drop  The Globe and Mail

Candel Reports 88 Percent Q2 Loss Drop - The Globe and Mail

Click here to get full coverage on Candel Therapeutics (CADL) Receives a Buy from Bank of America Securities - The Globe and Mail

Candel Therapeutics (CADL) Receives a Buy from Bank of America Securities  The Globe and Mail

Candel Therapeutics (CADL) Receives a Buy from Bank of America Securities - The Globe and Mail

Click here to get full coverage on Candel Therapeutics Stock Rallies On Canaccord’s Vote Of Confidence In Lead Cancer Drug: Retail Traders Rejoice - Stocktwits

Candel Therapeutics Stock Rallies On Canaccord’s Vote Of Confidence In Lead Cancer Drug: Retail Traders Rejoice  Stocktwits

Candel Therapeutics Stock Rallies On Canaccord’s Vote Of Confidence In Lead Cancer Drug: Retail Traders Rejoice - Stocktwits

Click here to get full coverage on Library patrons come for answers to food, housing, employment issues. Here’s how CADL helps - Lansing State Journal

Library patrons come for answers to food, housing, employment issues. Here’s how CADL helps  Lansing State Journal

Library patrons come for answers to food, housing, employment issues. Here’s how CADL helps - Lansing State Journal

Click here to get full coverage on symbol__ Stock Quote Price and Forecast - CNN

symbol__ Stock Quote Price and Forecast  CNN

symbol__ Stock Quote Price and Forecast - CNN

Click here to get full coverage on Lansing City Council opposes CADL's potential move from downtown branch - Lansing State Journal

Lansing City Council opposes CADL's potential move from downtown branch  Lansing State Journal

Lansing City Council opposes CADL's potential move from downtown branch - Lansing State Journal

Click here to get full coverage on Finding a potential new home for the Lansing library - WILX

Finding a potential new home for the Lansing library  WILX

Finding a potential new home for the Lansing library - WILX

Click here to get full coverage on Candel Therapeutics Stock Headed For 20% Weekly Gains: Retail Over The Moon With BofA's 'Buy' Call - Stocktwits

Candel Therapeutics Stock Headed For 20% Weekly Gains: Retail Over The Moon With BofA's 'Buy' Call  Stocktwits

Candel Therapeutics Stock Headed For 20% Weekly Gains: Retail Over The Moon With BofA's 'Buy' Call - Stocktwits

Click here to get full coverage on CADL Stock Soars as Phase III Prostate Cancer Study Meets Primary Goal - Yahoo Finance

CADL Stock Soars as Phase III Prostate Cancer Study Meets Primary Goal  Yahoo Finance

CADL Stock Soars as Phase III Prostate Cancer Study Meets Primary Goal - Yahoo Finance

Click here to get full coverage on Candel Therapeutics eyes CAN-2409 BLA filing, advances cancer pipeline - Proactive financial news

Candel Therapeutics eyes CAN-2409 BLA filing, advances cancer pipeline  Proactive financial news

CADL

Price Chart

Key Statistics

Technicals

About CADL

Latest News

Capital Area District Libraries announces plan to relocate Local History collection - WILX

Does Candel Therapeutics (CADL) Have the Potential to Rally 285.32% as Wall Street Analysts Expect? - Yahoo Finance

$CADL stock is down 9% today. Here's what we see in our data. - Quiver Quantitative

Advanced Charts

Top Gainers

Top Losers